Brokerages Set Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Price Target at $13.63

Shares of Bioceres Crop Solutions Corp. (NASDAQ:BIOX) have earned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $13.63.

A number of equities analysts have recently commented on BIOX shares. Canaccord Genuity Group raised shares of Bioceres Crop Solutions to a “strong-buy” rating in a research report on Friday, July 19th. Roth Mkm reduced their target price on shares of Bioceres Crop Solutions from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Oppenheimer reduced their target price on shares of Bioceres Crop Solutions from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 11th. Roth Capital raised shares of Bioceres Crop Solutions to a “strong-buy” rating in a research report on Tuesday, July 2nd. Finally, Lake Street Capital reduced their target price on shares of Bioceres Crop Solutions from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th.

Bioceres Crop Solutions Stock Up 0.8 %

Shares of NASDAQ:BIOX opened at $7.51 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.91 and a debt-to-equity ratio of 0.35. Bioceres Crop Solutions has a 12 month low of $7.35 and a 12 month high of $14.05. The company has a 50-day moving average price of $9.19 and a 200 day moving average price of $10.71. The company has a market cap of $471.61 million, a price-to-earnings ratio of 751.00 and a beta of 0.47.

Bioceres Crop Solutions (NASDAQ:BIOX) last announced its quarterly earnings results on Monday, September 9th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.23). Bioceres Crop Solutions had a net margin of 0.68% and a return on equity of 0.93%. The business had revenue of $124.30 million during the quarter, compared to the consensus estimate of $126.75 million. During the same period in the previous year, the business posted ($0.06) EPS. As a group, equities research analysts predict that Bioceres Crop Solutions will post 0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. purchased a new position in Bioceres Crop Solutions in the first quarter valued at $139,000. Lazard Asset Management LLC purchased a new stake in shares of Bioceres Crop Solutions during the first quarter worth about $212,000. Ping Capital Management Inc. purchased a new stake in shares of Bioceres Crop Solutions during the second quarter worth about $448,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Bioceres Crop Solutions during the second quarter worth about $472,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Bioceres Crop Solutions by 9.5% during the second quarter. Dimensional Fund Advisors LP now owns 61,330 shares of the company’s stock worth $688,000 after purchasing an additional 5,341 shares in the last quarter. Hedge funds and other institutional investors own 17.68% of the company’s stock.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.